retatrutide withdrawal Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide, an experimental weight-loss drug,

Further analyses revealed that retatrutide led to complete resolution of excess liver fat in approximately 80% of participants with hepatic steatosis after 24 weeks, increasing to about 90%

Improved cardiovascular health, better mental health, maintained functional capacity, and enhanced quality of life all favor active lifestyles regardless of pharmaceutical support

She had started to get her life back together

however, neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia [16]

This could diminish the unique advantage retatrutide holds over dual-agonists like tirzepatide

Yes, with continued use of your personalized plan and lifestyle adjustments, many users achieve lasting weight loss